SHORT MINI-FUTURE - GENMAB | Market Closed - Deutsche Boerse AG 01:42:27 2024-05-17 pm EDT | ||
| 30.37 EUR | -0.30% |
|
| 1 month | -1.56% | ||
| 3 months | -2.38% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 30.37 | -0.30% |
| 24-05-16 | 30.46 | +1.77% |
| 24-05-15 | 29.93 | -2.95% |
| 24-05-14 | 30.84 | +0.23% |
| 24-05-13 | 30.77 | -0.87% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 01:42 pm EDT
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VU0EMZ |
| ISIN | DE000VU0EMZ2 |
| Date issued | 2022-12-01 |
| Strike | 4,319 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 15.46 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 33.37 € |
|---|---|
| Lowest since issue | 13.81 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
2,041
DKK
Average target price
2,470
DKK
Spread / Average Target
+21.01%
- Stock Market
- Certificates
- Certificat
